Trials / Completed
CompletedNCT03058978
Assessing Ovarian Function During Prolonged Implant Use
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 117 (actual)
- Sponsor
- Planned Parenthood of the St. Louis Region and Southwest Missouri · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate how the ovaries may be functioning while using the the Implanon®/Nexplanon® during the three years beyond the FDA approved duration. Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws. Participants will be followed for 30 days.
Detailed description
This prospective cohort will evaluate the ovarian function of 210 ENG users during the three years beyond the FDA approved duration. Participants enrolled in the current study, EPIC (Evaluating the Prolonged Use of IUD and Implant for Contraception, NCT02267616), will be contacted via telephone, screened and scheduled to enroll in person. After the signed consent is obtained participants will be asked to complete a brief questionnaire on demographic information and bleeding patterns. Participants will undergo a blood draw to assess serum etonogestrel and serum progesterone levels. Follow up visits will include a weekly blood draw for three weeks to assess serum progesterone levels. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period. The investigators will enroll participants at seven time points; at method expiration (3 years of use), and in six-month intervals through six years of use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Etonogestrel Implant | Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period. |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
- First posted
- 2017-02-23
- Last updated
- 2022-07-12
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03058978. Inclusion in this directory is not an endorsement.